Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Pancreatic Neuroendocrine Neoplasm: early-phase trial registry
2 of 2 indexed Pancreatic Neuroendocrine Neoplasm trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #7,188 of 28,707 conditions by registered trial count.
2 US clinical trials · 2 currently recruiting · #7,188 of 28,707 conditions by registered trial count
Pancreatic Neuroendocrine Neoplasm: 2 US clinical trials tracked, 2 recruiting.
Pancreatic Neuroendocrine Neoplasm is the subject of 2 registered US clinical trials on ClinicalTrials.gov, 2 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 1 in Phase 1-2 (earlier-stage). The most active sponsor is Roswell Park Cancer Institute, running 1 of these trials.
Enrollment posture brief
Registry condition pancreatic-neuroendocrine-neoplasm
OPEN 2 | RECR 100% | LATE 0 | EARLY 1 | RANK #7188 | SPON 1
Volume-matched condition peers
Nearest open-share peer: Aortic Arch Aneurysm (100% recruiting · 5 trials)
Pancreatic Neuroendocrine Neoplasm lists 2 open slots (100% of 2 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Pancreatic Neuroendocrine Neoplasm on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Pancreatic Neuroendocrine Neoplasm is recruiting above its size-band peers.
2 of 2 indexed trials (100%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
Open and recent trials
2 total, page 1 of 1
Genetic Predisposition Testing Program for Pancreatic Neuroendocrine Neoplasms
University of California, San Francisco
NCT05746182
Temozolomide and Survivin Long Peptide Vaccine (SurVaxM) for the Treatment of Patients With Progressing Metastatic Neuroendocrine Carcinomas
Roswell Park Cancer Institute
NCT06202066
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 2 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Pancreatic Neuroendocrine Neoplasm records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Pancreatic Neuroendocrine Neoplasm trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Pancreatic Neuroendocrine Neoplasm page
2 registered trials, 2 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 2 Pancreatic Neuroendocrine Neoplasm trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Roswell Park Cancer Institute sponsors the most Pancreatic Neuroendocrine Neoplasm trials on record, review their full trial history before evaluating a specific study. See Roswell Park Cancer Institute's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Pancreatic Neuroendocrine Neoplasm condition card totals 2 registered trials; most-linked intervention Hereditary Cancer Panel; top US site state New York. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.